<--- Back to Details
First PageDocument Content
Motor neurone disease / Spinal muscular atrophy / RNA splicing / Applied genetics / Biotechnology / SMN1 / Antisense therapy / Survival of motor neuron / SMN2 / Genetics / Biology / Spliceosome
Date: 2013-04-29 02:31:53
Motor neurone disease
Spinal muscular atrophy
RNA splicing
Applied genetics
Biotechnology
SMN1
Antisense therapy
Survival of motor neuron
SMN2
Genetics
Biology
Spliceosome

npg Call in the backup The most common genetic killer of infants, a disease known as spinal muscular atrophy, is caused by mutations in a single gene. The human genome contains its own backup system—near-identical cop

Add to Reading List

Source URL: www.fsma.org.hk

Download Document from Source Website

File Size: 2,11 MB

Share Document on Facebook

Similar Documents

npg  Call in the backup The most common genetic killer of infants, a disease known as spinal muscular atrophy, is caused by mutations in a single gene. The human genome contains its own backup system—near-identical cop

npg Call in the backup The most common genetic killer of infants, a disease known as spinal muscular atrophy, is caused by mutations in a single gene. The human genome contains its own backup system—near-identical cop

DocID: 177oq - View Document

ISIS INITIATES PHASE 1 CLINICAL STUDY OF ISIS-SMNRX IN PATIENTS WITH SPINAL MUSCULAR ATROPHY U.S. FDA has granted both Fast Track Status and Orphan Drug Designation for ISIS-SMNRx CARLSBAD, Calif., December 19, 2011 –

ISIS INITIATES PHASE 1 CLINICAL STUDY OF ISIS-SMNRX IN PATIENTS WITH SPINAL MUSCULAR ATROPHY U.S. FDA has granted both Fast Track Status and Orphan Drug Designation for ISIS-SMNRx CARLSBAD, Calif., December 19, 2011 –

DocID: 15Kdp - View Document

ISSNBiopolymers and CellVol. 26. N 1  Implementation of the quantitative Real-Time PCR for the molecular-genetic diagnostics of spinal muscular atrophy O. O. Soloviov, G. B. Livshits, S. S. Podlesnaya

ISSNBiopolymers and CellVol. 26. N 1 Implementation of the quantitative Real-Time PCR for the molecular-genetic diagnostics of spinal muscular atrophy O. O. Soloviov, G. B. Livshits, S. S. Podlesnaya

DocID: 13lsk - View Document

BioMed Research International Special Issue on Motor Neuron Disorders: Molecular Mechanisms of Pathogenesis and Therapeutic Developments  CALL FOR PAPERS

BioMed Research International Special Issue on Motor Neuron Disorders: Molecular Mechanisms of Pathogenesis and Therapeutic Developments CALL FOR PAPERS

DocID: 12fvF - View Document

Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1  This study is a phase I, single-site, dose escalation study to evaluate the safety and efficacy of gene transfer for Spinal Muscular Atrophy Type 1 (SMA1).

Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 This study is a phase I, single-site, dose escalation study to evaluate the safety and efficacy of gene transfer for Spinal Muscular Atrophy Type 1 (SMA1).

DocID: 11rVr - View Document